发布求助
文献互助 智能选刊 最新文献

Adverse Drug Reaction Bulletin最新文献

筛选
英文 中文
A fatal outcome due to a continuous dosage of gentamicin: a case report 持续服用庆大霉素导致的致命后果：一份病例报告
Adverse Drug Reaction Bulletin Pub Date : 2024-02-01 DOI: 10.1097/fad.0000000000000072
Gerard Ronda-Roca, A. Sancho-López, Belén Ruiz-Antorán, Esther Montero-Hernández, Alicia San Martin-Espinosa
{"title":"A fatal outcome due to a continuous dosage of gentamicin: a case report","authors":"Gerard Ronda-Roca, A. Sancho-López, Belén Ruiz-Antorán, Esther Montero-Hernández, Alicia San Martin-Espinosa","doi":"10.1097/fad.0000000000000072","DOIUrl":"https://doi.org/10.1097/fad.0000000000000072","url":null,"abstract":"\u0000 \u0000 Gentamicin, an aminoglycoside antibiotic, exerts its bactericidal effect primarily through the inhibition of ribosomes in Gram-negative bacteria. It has a concentration-dependent pharmacodynamic effect, making an extended-interval dosage preferable. The total dose is, therefore, usually administered as a single daily dose instead of divided portions two or three times a day. This dosage has shown an excellent efficacy because an appropriate peak concentration is obtained, whilst the risk of nephrotoxicity is reduced as this is correlated with the residual concentration of gentamicin. In the European Medicines Agencies Summary of Products Characteristics, it is stated that deterioration of kidney function could be expected in 1/10 to 1/100 patients treated with gentamicin. We present a 92-year-old female patient with a weight of 39 kg, history of chronic kidney disease (CKD) and chronic heart failure that presented a fatal nephrotoxicity due to a prescription error of gentamicin.\u0000","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139812290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A fatal outcome due to a continuous dosage of gentamicin: a case report 持续服用庆大霉素导致的致命后果：一份病例报告
Adverse Drug Reaction Bulletin Pub Date : 2024-02-01 DOI: 10.1097/fad.0000000000000072
Gerard Ronda-Roca, A. Sancho-López, Belén Ruiz-Antorán, Esther Montero-Hernández, Alicia San Martin-Espinosa
{"title":"A fatal outcome due to a continuous dosage of gentamicin: a case report","authors":"Gerard Ronda-Roca, A. Sancho-López, Belén Ruiz-Antorán, Esther Montero-Hernández, Alicia San Martin-Espinosa","doi":"10.1097/fad.0000000000000072","DOIUrl":"https://doi.org/10.1097/fad.0000000000000072","url":null,"abstract":"\u0000 \u0000 Gentamicin, an aminoglycoside antibiotic, exerts its bactericidal effect primarily through the inhibition of ribosomes in Gram-negative bacteria. It has a concentration-dependent pharmacodynamic effect, making an extended-interval dosage preferable. The total dose is, therefore, usually administered as a single daily dose instead of divided portions two or three times a day. This dosage has shown an excellent efficacy because an appropriate peak concentration is obtained, whilst the risk of nephrotoxicity is reduced as this is correlated with the residual concentration of gentamicin. In the European Medicines Agencies Summary of Products Characteristics, it is stated that deterioration of kidney function could be expected in 1/10 to 1/100 patients treated with gentamicin. We present a 92-year-old female patient with a weight of 39 kg, history of chronic kidney disease (CKD) and chronic heart failure that presented a fatal nephrotoxicity due to a prescription error of gentamicin.\u0000","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"7 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139872214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subject and Drug Indexes to Adverse Drug Reaction Bulletin: Nos 338–343 February 2023 – December 2023 药物不良反应公告》主题和药物索引：第 338-343 期 2023 年 2 月 - 2023 年 12 月
Adverse Drug Reaction Bulletin Pub Date : 2023-12-01 DOI: 10.1097/01.fad.0000997896.20819.3a
{"title":"Subject and Drug Indexes to Adverse Drug Reaction Bulletin: Nos 338–343 February 2023 – December 2023","authors":"","doi":"10.1097/01.fad.0000997896.20819.3a","DOIUrl":"https://doi.org/10.1097/01.fad.0000997896.20819.3a","url":null,"abstract":"","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"357 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138625770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic outcomes arising from adverse drug reactions 药物不良反应引起的治疗结果
Adverse Drug Reaction Bulletin Pub Date : 2023-12-01 DOI: 10.1097/FAD.0000000000000071
I. M. Heerfordt, Iben Rix, Henrik Horwitz
{"title":"Therapeutic outcomes arising from adverse drug reactions","authors":"I. M. Heerfordt, Iben Rix, Henrik Horwitz","doi":"10.1097/FAD.0000000000000071","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000071","url":null,"abstract":"Summary This article examines five cases where unintended adverse reactions have led to new therapeutic outcomes. The cases cover subsequent applications of acetylsalicylic acid, sildenafil, thalidomide, domperidone, and disulfiram. These examples demonstrate the versatility of drugs in addressing diverse medical challenges. The discussion highlights the importance of analyzing adverse drug reactions to identify therapeutic opportunities arising from adverse reactions.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"41 2‐3","pages":"1331 - 1334"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138621861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolution of pharmacovigilance: the contributions of Michael D Rawlins 药物警戒的演变:Michael D Rawlins的贡献
Adverse Drug Reaction Bulletin Pub Date : 2023-10-01 DOI: 10.1097/fad.0000000000000070
Philip A. Routledge
{"title":"The evolution of pharmacovigilance: the contributions of Michael D Rawlins","authors":"Philip A. Routledge","doi":"10.1097/fad.0000000000000070","DOIUrl":"https://doi.org/10.1097/fad.0000000000000070","url":null,"abstract":"Summary In the last 175 years, pharmacovigilance has evolved, albeit sometimes in response to serious incidents. The late Professor Sir Michael D Rawlins made major contributions to pharmacovigilance internationally. He proposed a widely used classification of adverse drug reactions (ADRs). He highlighted the importance of post-marketing surveillance immediately after a medicine's launch, and the strengths and weaknesses of existing spontaneous suspected ADR reporting systems. He encouraged the broadening of pharmacovigilance to involve all health professional groups, as well as patients. He highlighted the value of all sources of evidence and of judgement in making risk-benefit assessments. He was a strong early advocate of greater use of databases and registries, and of continuing surveillance throughout the lifespan of medicines as therapeutic agents.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136094326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of pharmacologically induced lactation 药物诱导泌乳的安全性
Adverse Drug Reaction Bulletin Pub Date : 2023-08-01 DOI: 10.1097/fad.0000000000000069
Patrick L. Thøgersen, D. Gotfredsen, Christina Gade, Henrik Horwitz, J. T. Andersen
{"title":"Safety of pharmacologically induced lactation","authors":"Patrick L. Thøgersen, D. Gotfredsen, Christina Gade, Henrik Horwitz, J. T. Andersen","doi":"10.1097/fad.0000000000000069","DOIUrl":"https://doi.org/10.1097/fad.0000000000000069","url":null,"abstract":"\u0000 \u0000 Pharmacologically induced lactation has the potential to help parents of all sexes who wish to breastfeed their children without a preceding pregnancy, and the interest in this possibility is increasing. A combination of hormones, physical stimulation and domperidone to mimic the hormonal changes of pregnancy and birth can be used to induce lactation. However, off-label uses of estrogen, progestin and domperidone or metoclopramide in high doses and for a long period of time have been associated with adverse drug reactions. Before prescribing drugs for induced lactation, it is important to discuss and help manage the parent's expectations regarding the outcome and, in detail, discuss the potential risks.\u0000","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41341728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment 在酒精戒断治疗中使用氯二氮卓延长镇静时间的风险
Adverse Drug Reaction Bulletin Pub Date : 2023-06-01 DOI: 10.1097/FAD.0000000000000068
Nanna Reiter, C. Andersen, K. Thomsen, C. Wamberg, T. Petersen, K. Dalhoff
{"title":"Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment","authors":"Nanna Reiter, C. Andersen, K. Thomsen, C. Wamberg, T. Petersen, K. Dalhoff","doi":"10.1097/FAD.0000000000000068","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000068","url":null,"abstract":"Summary The use of chlordiazepoxide in the treatment of alcohol withdrawal symptoms poses a risk of prolonged sedation with the need of weeks lasting antidote treatment, and extended hospitalization due to active metabolites with very long half-lives. We present four case stories to elucidate this issue. One patient received 800 mg chlordiazepoxide and was treated with flumazenil for 42 days. Another patient was treated with 100 mg chlordiazepoxide. 5 days after administration of chlordiazepoxide, concentrations of chlordiazepoxide and its active metabolite demoxepam, were within therapeutic range, the patient was treated with flumazenil for 6 days. He died after palliative care. The great individual variation in the clinical effect of chlordiazepoxide depends on the activity of the CYP P450 system, especially CYP3A4/A5 and CYPS2C19, which can be impaired in cirrhotic and elderly patients.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"340 1","pages":"1319 - 1322"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44317592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review 胰高血糖素样肽-1受体激动剂用于成人、青少年和儿童肥胖体重管理的安全性：范围界定综述
Adverse Drug Reaction Bulletin Pub Date : 2023-04-01 DOI: 10.1097/FAD.0000000000000067
Christoffer S. Baden, J. T. Andersen, M. Christensen, Christina Gade
{"title":"Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review","authors":"Christoffer S. Baden, J. T. Andersen, M. Christensen, Christina Gade","doi":"10.1097/FAD.0000000000000067","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000067","url":null,"abstract":"Summary As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"339 1","pages":"1315 - 1318"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48207702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Controversial preservation of eye drops: the toxicity of benzalkonium chloride 有争议的眼药水保存:苯扎氯铵的毒性
Adverse Drug Reaction Bulletin Pub Date : 2023-02-01 DOI: 10.1097/FAD.0000000000000066
A. Hedengran, M. Kolko
{"title":"Controversial preservation of eye drops: the toxicity of benzalkonium chloride","authors":"A. Hedengran, M. Kolko","doi":"10.1097/FAD.0000000000000066","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000066","url":null,"abstract":"Summary Eye drops are a major cornerstone in the treatment of ophthalmic diseases, and adherence is crucial. Most eye drops are preserved with the surfactant benzalkonium chloride (BAK). Great controversy revolves around the use of BAK, as BAK has continuously been proven to be cytotoxic. In cell cultures, BAK-preserved eye drops cause increased cell death, and in patients, preservation with BAK causes more side effects and ocular surface damage. Side effects can negatively affect adherence and, with this, disease control. This is namely a problem in glaucoma patients. Glaucoma is irreversible, and a lack of disease control may lead to incurable blindness. The purposes of treating ophthalmic diseases are to secure good visual acuity, ocular comfort, and good quality of life for the patients. When administering, BAK-preserved eye drops ocular damage may be inflicted and these purposes are put at risk. Preservative-free and alternatively preserved eye drops are available, why there is no need for the use of BAK.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"338 1","pages":"1311 - 1314"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of naproxen for fever and acute pain in preschool children: a systematic review 萘普生治疗学龄前儿童发热和急性疼痛的安全性和有效性:一项系统综述
Adverse Drug Reaction Bulletin Pub Date : 2022-12-01 DOI: 10.1097/FAD.0000000000000065
S. Mathiesen, Adam Jorgensen
{"title":"Safety and efficacy of naproxen for fever and acute pain in preschool children: a systematic review","authors":"S. Mathiesen, Adam Jorgensen","doi":"10.1097/FAD.0000000000000065","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000065","url":null,"abstract":"Summary Preschool children may require acute pain and fever management beyond the effects of paracetamol. Ibuprofen, an NSAID, is the first-choice analgesic add-on in children, as its effects and safety profile are well-known in children. In some countries, however, ibuprofen in oral solution is not available; thus, naproxen (another NSAID) could be an alternative. In this systematic review, we evaluated the effect of naproxen on fever and acute pain as well as related adverse events in preschool children. Although the evidence was limited, naproxen appears to be well tolerated and efficient in treating acute pain and fever in preschool children.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"337 1","pages":"1307 - 1310"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45297697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信